早期药物发现中的新化学模式与战略思维
New Chemical Modalities and Strategic Thinking in Early Drug Discovery.
作者信息
Blanco Maria-Jesus, Gardinier Kevin M
机构信息
Sage Therapeutics, Inc., Medicinal Chemistry, 215 First Street, Cambridge, Massachusetts 02142, United States.
Novartis Institutes for BioMedical Research, Global Discovery Chemistry, 22 Windsor Street, Cambridge, Massachusetts 02139, United States.
出版信息
ACS Med Chem Lett. 2020 Jan 14;11(3):228-231. doi: 10.1021/acsmedchemlett.9b00582. eCollection 2020 Mar 12.
Abstract
The classical toolbox for drug discovery is continuously expanding beyond traditional small molecules. New chemical modalities including RNA therapeutics, protein degraders, cyclopeptides, antibody drug conjugates, and gene therapy have matured, demonstrating clinical success and are now considered early in target appraisal. In this Viewpoint, we highlight recent progress in the field.
摘要
药物研发的经典工具库正在不断扩展，超越了传统小分子药物的范畴。包括RNA疗法、蛋白质降解剂、环肽、抗体药物偶联物和基因疗法在内的新化学模式已经成熟，展现出临床成效，目前被视为靶点评估的早期阶段。在本观点文章中，我们重点介绍了该领域的最新进展。
相似文献
1
New Chemical Modalities and Strategic Thinking in Early Drug Discovery.早期药物发现中的新化学模式与战略思维
ACS Med Chem Lett. 2020 Jan 14;11(3):228-231. doi: 10.1021/acsmedchemlett.9b00582. eCollection 2020 Mar 12.
2
Antibody Conjugates-Recent Advances and Future Innovations.抗体偶联物——最新进展与未来创新
Antibodies (Basel). 2020 Jan 8;9(1):2. doi: 10.3390/antib9010002.
3
New horizons in therapeutic antibody discovery: opportunities and challenges versus small-molecule therapeutics.治疗性抗体发现的新视野：与小分子疗法相比的机遇与挑战
J Biomol Screen. 2015 Apr;20(4):437-53. doi: 10.1177/1087057114562544. Epub 2014 Dec 15.
4
Pharmacokinetic and Drug Metabolism Properties of Novel Therapeutic Modalities.新型治疗模式的药代动力学和药物代谢特性。
Drug Metab Dispos. 2019 Oct;47(10):1097-1099. doi: 10.1124/dmd.119.088708. Epub 2019 Aug 9.
5
Innovative Linker Strategies for Tumor-Targeted Drug Conjugates.创新的连接子策略用于肿瘤靶向药物偶联物。
Chemistry. 2019 Nov 22;25(65):14740-14757. doi: 10.1002/chem.201903127. Epub 2019 Sep 20.
6
Metabolism of new drug modalities research advances - 2023 year in review.新型药物模式代谢研究进展——2023 年度回顾。
Drug Metab Rev. 2024 Aug;56(3):223-246. doi: 10.1080/03602532.2024.2370331. Epub 2024 Jul 5.
7
Advancing New Chemical Modalities into Clinical Studies.推进新型化学药物进入临床研究。
ACS Med Chem Lett. 2022 Oct 27;13(11):1691-1698. doi: 10.1021/acsmedchemlett.2c00375. eCollection 2022 Nov 10.
8
[Aiming for zero blindness].追求零失明
Nippon Ganka Gakkai Zasshi. 2015 Mar;119(3):168-93; discussion 194.
9
New Modalities for Challenging Targets in Drug Discovery.新药研发中极具挑战性靶点的新方法
Angew Chem Int Ed Engl. 2017 Aug 21;56(35):10294-10323. doi: 10.1002/anie.201611914. Epub 2017 Jul 24.
10
Current issues of RNAi therapeutics delivery and development.RNAi 治疗药物递送与研发的当前问题。
J Control Release. 2014 Dec 10;195:49-54. doi: 10.1016/j.jconrel.2014.07.056. Epub 2014 Aug 9.
引用本文的文献
1
Linker Methylation as a Strategy to Enhance PROTAC Oral Bioavailability: Insights from Molecular Properties and Conformational Analysis.连接子甲基化作为提高PROTAC口服生物利用度的策略：来自分子性质和构象分析的见解
J Med Chem. 2025 Aug 14;68(15):16666-16677. doi: 10.1021/acs.jmedchem.5c01497. Epub 2025 Jul 31.
2
From Concepts to Inhibitors: A Blueprint for Targeting Protein-Protein Interactions.从概念到抑制剂：靶向蛋白质-蛋白质相互作用的蓝图
Chem Rev. 2025 Jul 23;125(14):6819-6869. doi: 10.1021/acs.chemrev.5c00046. Epub 2025 Jun 24.
3
A comprehensive review of 20 years of progress in nonclinical QT evaluation and proarrhythmic assessment.对非临床QT评估和致心律失常性评估20年进展的全面综述。
J Pharmacokinet Pharmacodyn. 2025 May 16;52(3):32. doi: 10.1007/s10928-025-09979-2.
4
Macrocyclization: Enhancing Drug-like Properties of Discoidin Domain Receptor Kinase Inhibitors.大环化：增强盘状结构域受体激酶抑制剂的类药性质
ACS Med Chem Lett. 2025 Apr 7;16(5):784-789. doi: 10.1021/acsmedchemlett.4c00611. eCollection 2025 May 8.
5
The Evolution of Fluorescein into A Potential Theranostic Tool.荧光素向潜在诊疗工具的演变。
Chemistry. 2025 Jun 17;31(34):e202501513. doi: 10.1002/chem.202501513. Epub 2025 May 13.
6
Exploring chemical space for "druglike" small molecules in the age of AI.在人工智能时代探索“类药物”小分子的化学空间。
Front Mol Biosci. 2025 Mar 17;12:1553667. doi: 10.3389/fmolb.2025.1553667. eCollection 2025.
7
Targeting Tau Protein with Proximity Inducing Modulators: A New Frontier to Combat Tauopathies.用邻近诱导调节剂靶向tau蛋白：对抗tau蛋白病的新前沿。
ACS Pharmacol Transl Sci. 2025 Feb 10;8(3):654-672. doi: 10.1021/acsptsci.4c00733. eCollection 2025 Mar 14.
8
An engineered aldolase enables the biocatalytic synthesis of 2'-functionalized nucleoside analogues.一种工程化醛缩酶能够实现2'-官能化核苷类似物的生物催化合成。
Nat Synth. 2025;4(2):156-166. doi: 10.1038/s44160-024-00671-w. Epub 2024 Nov 5.
9
How Should we Teach Medicinal Chemistry in Higher Education to Prepare Students for a Future Career as Medicinal Chemists and Drug Designers? - A Teacher's Perspective.在高等教育中，我们应如何教授药物化学，以使学生为未来成为药物化学家和药物设计师做好准备？——一位教师的视角
ChemMedChem. 2025 Jan 14;20(2):e202400791. doi: 10.1002/cmdc.202400791. Epub 2024 Nov 20.
10
Exploring the Potential of Adaptive, Local Machine Learning in Comparison to the Prediction Performance of Global Models: A Case Study from Bayer's Caco-2 Permeability Database.与全局模型预测性能相比，探索自适应局部机器学习的潜力：来自拜耳公司Caco-2通透性数据库的案例研究。
J Chem Inf Model. 2024 Dec 23;64(24):9163-9172. doi: 10.1021/acs.jcim.4c01083. Epub 2024 Nov 20.
本文引用的文献
1
Peptide-Cleavable Self-immolative Maytansinoid Antibody-Drug Conjugates Designed To Provide Improved Bystander Killing.设计用于增强旁观者杀伤作用的可肽裂解的自毁型美登素类抗体药物偶联物
ACS Med Chem Lett. 2019 Sep 27;10(10):1393-1399. doi: 10.1021/acsmedchemlett.9b00310. eCollection 2019 Oct 10.
2
PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.蛋白酶靶向嵌合体（PROTACs）——过去、现在与未来。
Drug Discov Today Technol. 2019 Apr;31:15-27. doi: 10.1016/j.ddtec.2019.01.002. Epub 2019 Feb 13.
3
Why Some Targets Benefit from beyond Rule of Five Drugs.为什么有些靶标受益于超出五规则的药物。
J Med Chem. 2019 Nov 27;62(22):10005-10025. doi: 10.1021/acs.jmedchem.8b01732. Epub 2019 Jun 26.
4
2018 FDA Tides Harvest.2018年美国食品药品监督管理局潮汐收获。 （不过这个表述似乎不太常见或不太准确，可能存在信息不完整或有误的情况）
Pharmaceuticals (Basel). 2019 Apr 5;12(2):52. doi: 10.3390/ph12020052.
5
Targeting RNA with Small Molecules To Capture Opportunities at the Intersection of Chemistry, Biology, and Medicine.靶向小分子 RNA 以捕捉化学、生物学和医学交叉点的机会。
J Am Chem Soc. 2019 May 1;141(17):6776-6790. doi: 10.1021/jacs.8b13419. Epub 2019 Apr 19.
6
Macrocyclic Peptides as Drug Candidates: Recent Progress and Remaining Challenges.作为药物候选物的大环肽：最新进展和尚存的挑战。
J Am Chem Soc. 2019 Mar 13;141(10):4167-4181. doi: 10.1021/jacs.8b13178. Epub 2019 Feb 27.
7
The Next Phase of Human Gene-Therapy Oversight.人类基因治疗监管的下一阶段。
N Engl J Med. 2018 Oct 11;379(15):1393-1395. doi: 10.1056/NEJMp1810628. Epub 2018 Aug 15.
8
Constrained peptides' time to shine?受限肽发光的时候到了？
Nat Rev Drug Discov. 2018 Jul 30;17(8):531-533. doi: 10.1038/nrd.2018.125.
9
Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment.口服司美格鲁肽在肾功能损害受试者中的药代动力学、安全性和耐受性。
Clin Pharmacokinet. 2018 Dec;57(12):1571-1580. doi: 10.1007/s40262-018-0649-2.
10
Cyclic peptide natural products chart the frontier of oral bioavailability in the pursuit of undruggable targets.环肽天然产物在追求难以成药靶点的过程中勾勒出了口服生物利用度的前沿领域。
Curr Opin Chem Biol. 2017 Jun;38:141-147. doi: 10.1016/j.cbpa.2017.04.012. Epub 2017 May 29.
Zotero 插件